EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Multizentrische StudieOpen Access

High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)

Sharon A Riddler iD, Zoe Moodie iD, Jesse Clark iD, Catherine Yen, Mary Allen iD, Briana D Furch, Huiyin Lu, Shannon Grant, Kajari Mondal, Maija Anderson, Janine Maenza, Maria P Lemos iD und 12 weitere

Annals of Internal Medicine · 2025-07 · 178 (7) · 963-974

DOI: 10.7326/annals-24-02701 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2025-07. Verfasst von Sharon A Riddler und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (S.A.R.). Hauptthemen laut MEDLINE: AIDS Vaccines, HIV-1, Chronic Urticaria. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The mRNA platform is under investigation for many vaccines, including HIV-1 vaccines. OBJECTIVE: To evaluate the safety and tolerability of 3 investigational HIV-1 trimer mRNA vaccines. DESIGN: Safety analysis of mRNA vaccination in a phase 1, randomized, open-label trial. (ClinicalTrials.gov: NCT05217641). SETTING: Ten research sites in the United States. PARTICIPANTS: 108 volunteers aged 18 to 55 years without HIV-1. INTERVENTION: Investigational HIV-1 BG505 MD39.3 trimer mRNA vaccines (gp140 soluble trimer, gp151 membrane-bound trimer, and gp151 CD4KO membrane-bound trimer) at doses of 100 and 250 mcg at 0, 2, and 6 months. MEASUREMENTS: Solicited and unsolicited adverse reactions and events reported during the 12 months after the first vaccination. RESULTS: Participants (n = 108) were randomly assigned to 6 vaccine groups. Mild to moderate local and systemic solicited events were common. Eighty participants reported 190 unsolicited adverse events (AEs); 30 were considered to be related to a study product. Most (73%) related AEs were mild, and the rest were moderate. Among related AEs, urticaria was reported by 7 of 108 participants (7% [95% CI, 3% to 13%]), 4 of whom had unresolved, intermittent urticaria at 12 months. In post hoc analyses, demographic characteristics, history of allergy or medication use, and COVID-19 were not associated with urticaria. In a comparison of participants with versus without urticaria, 100% (7 of 7; CI, 65% to 100%) versus 37% (37 of 101; CI, 28% to 46%) reported previous Moderna COVID-19 vaccination, 29% (2 of 7; CI, 8% to 64%) versus 76% (77 of 101; CI, 67% to 84%) reported previous Pfizer-BioNTech COVID-19 vaccination, and 0% (0 of 7; CI, 0% to 35%) versus 5% (5 of 101; CI, 2% to 11%) reported no previous mRNA COVID-19 vaccination. LIMITATIONS: Lack of a placebo group, open-label study, and post hoc evaluation of urticarial risk. CONCLUSION: Urticarial reactions associated with experimental HIV-1 mRNA vaccines were observed in this trial. Studies to investigate the mechanism and approaches to mitigate these reactions are underway to further advance HIV-1 vaccine research. PRIMARY FUNDING SOURCE: National Institutes of Health, National Institute of Allergy and Infectious Diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV-1Chronic UrticariaHumansAdultMaleFemaleMiddle AgedHIV InfectionsYoung AdultAdolescentmRNA VaccinesVaccines, SyntheticUnited States

Substanzen

AIDS VaccinesmRNA VaccinesVaccines, Synthetic

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (S.A.R.).
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington (Z.M., B.D.F., H.L., S.G., K.M., M.Anderson, J.M., M.P.L., A.S.W.D., M.J.M., J.G.K., L.C.).
  • Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California (J.C.).
  • Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland (C.Y., M.Allen).
  • Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (S.R.W., L.R.B.).
  • Division of Infectious Diseases, Aaron Diamond AIDS Research Center, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, New York (M.E.S.).

ORCID-Profile: Sharon A Riddler, Zoe Moodie, Jesse Clark, Mary Allen, Maria P Lemos, Amanda S Woodward Davis, Stephen R Walsh, Ian Frank, Kathryn E Stephenson, Lawrence Corey

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Riddler, S. A., Moodie, Z., Clark, J., Yen, C., Allen, M., Furch, B. D., Lu, H., Grant, S., Mondal, K., Anderson, M., Maenza, J., Lemos, M. P., Woodward Davis, A. S., Walsh, S. R., Sobieszczyk, M. E., Frank, I., Goepfert, P., Stephenson, K. E., Baden, L. R., …, & Corey, L. (2025). High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). Annals of Internal Medicine, 178(7), 963-974. https://doi.org/10.7326/annals-24-02701

Vancouver

Riddler SA, Moodie Z, Clark J, Yen C, Allen M, Furch BD, et al. High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302). Annals of Internal Medicine. 2025;178(7):963-974. doi:10.7326/annals-24-02701

BibTeX
@article{Riddler2025,
  author = {Riddler, Sharon A and Moodie, Zoe and Clark, Jesse and Yen, Catherine and Allen, Mary and Furch, Briana D and Lu, Huiyin and Grant, Shannon and Mondal, Kajari and Anderson, Maija and Maenza, Janine and Lemos, Maria P and Woodward Davis, Amanda S and Walsh, Stephen R and Sobieszczyk, Magdalena E and Frank, Ian and Goepfert, Paul and Stephenson, Kathryn E and Baden, Lindsey R and Tieu, Hong-Van and Keefer, Michael C and McElrath, M Juliana and Kublin, James G and Corey, Lawrence},
  title = {High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {7},
  pages = {963--974},
  doi = {10.7326/annals-24-02701}
}
Kostenlos starten →